Frontier Biotechnologies(SH:688221) Di Yi Cai Jing Zi Xun·2026-02-25 04:06Group 1 - Frontier Biotech's stock price plummeted by 16.19% on February 25, 2023, after a significant drop of 15.59% earlier in the day, making it the largest decline in the A-share market, with a market capitalization of 7.806 billion yuan [2] - The stock's decline followed the announcement of an exclusive licensing agreement with GlaxoSmithKline (GSK) on February 23, 2023, which granted GSK exclusive rights to develop, manufacture, and commercialize two small RNA (siRNA) pipeline products globally [2] - The agreement includes an upfront payment of 40 million USD and a milestone payment of 13 million USD, with potential additional payments of up to 950 million USD based on successful development, regulatory, and commercialization milestones, along with tiered royalties on global net sales [2] Group 2 - Prior to the stock drop, Frontier Biotech's stock had increased by 9.29% on February 24, 2023, due to the positive impact of the licensing agreement, but the subsequent decline erased those gains [3] - The company has commercialized products but is still operating at a loss, with a projected revenue of approximately 140 million to 145 million yuan for the fiscal year 2025, representing a year-on-year increase of 8.13% to 11.99% [3] - The expected net loss attributable to shareholders for 2025 is estimated to be between 255 million and 290 million yuan [3]